Picture of Evotec SE logo

EVT — Evotec SE News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

Brief: Evotec Confirms Guidance For 2024

Nov 6 (Reuters) - EVOTEC SE  EVTG.DE :
    * GUIDANCE FOR 2024 CONFIRMED
    * 9M ADJUSTED GROUP EBITDA TOTALLED EUR (6.0) M (9M 2023:
EUR 50.2
M)
    * OUTLOOK 2024: RESEARCH AND DEVELOPMENT EXPENDITURES ARE
EXPECTED
IN A RANGE OF EUR 50 - 60 M (2023: EUR 64.8 M)
    * ONE-OFF COSTS RELATED TO PRIORITY RESET MEASURES
RECOGNISED AT
EUR 62.3 M AS OF Q3, LOWER THAN INITIAL PROVISION OF EUR 68.5 M
ON 30 JUNE 2024
    * PRIORITY RESET IS SET TO YIELD AN ANNUALISED ADJUSTED
EBITDA
IMPROVEMENT OF OVER EUR 40 M, STARTING H2 2024

Source text:  ID:nEQ3Vh5XQa 
Further company coverage:  EVTG.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Evotec SE

See all news